Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related diseases.
Vonoprazan is a member of a new class of acid suppressants; potassium-competitive
acid blockers. Vonoprazan may thus be an alternative to PPIs.